Naba Alsaha Medical Services Co. reported a net profit decline of 58% to SAR 21.8 million in 2024, compared to SAR 52.4 million in 2023.
Item | 2023 | 2024 | Change |
---|---|---|---|
Revenues | 182.35 | 194.28 | 6.5 % |
Gross Income | 73.77 | 62.36 | (15.5 %) |
Operating Income | 42.97 | 24.52 | (42.9 %) |
Net Income | 52.38 | 21.78 | (58.4 %) |
Average Shares | 10.50 | 10.50 | - |
Earnings Per Share before unusual items | 4.07 | 2.07 | (49.0 %) |
EPS (Riyals) | 4.99 | 2.07 | (58.4 %) |
The profit drop was attributed to a 21% year-on-year (YoY) increase in revenue costs due to the rise in medical staff and the expansion of medical services. The company expects this expansion to positively impact the quality and diversity of the medical services provided, resulting in future revenue growth.
Additionally, the company added new assets, including medical equipment and residential buildings for employees, resulting in higher depreciation expenses.
Moreover, the financial results for 2023 included a non-recurring profit of SAR 9.6 million from the acquisition of Al-Anwar Medical Co. in Hail.
Zakat expenses increased by 32% YoY, in addition to a 9% increase in the company’s share of losses in the results of an associate company.
Item | H2 2023 | H2 2024 | Change |
---|---|---|---|
Revenues | 100.51 | 98.01 | (2.5 %) |
Gross Income | 40.14 | 30.84 | (23.2 %) |
Operating Income | 24.31 | 9.83 | (59.5 %) |
Net Income | 24.61 | 8.74 | (64.5 %) |
Average Shares | 10.50 | 10.50 | - |
Earnings Per Share before unusual items | 2.34 | 0.83 | (64.5 %) |
EPS (Riyals) | 2.34 | 0.83 | (64.5 %) |
Item | H1 2024 | H2 2024 | Change |
---|---|---|---|
Revenues | 96.27 | 98.01 | 1.8 % |
Gross Income | 31.53 | 30.84 | (2.2 %) |
Operating Income | 14.69 | 9.83 | (33.1 %) |
Net Income | 13.04 | 8.74 | (33.0 %) |
Average Shares | 10.50 | 10.50 | - |
Earnings Per Share before unusual items | 1.24 | 0.83 | (33.0 %) |
EPS (Riyals) | 1.24 | 0.83 | (33.0 %) |
On the other hand, Naba Alsaha recorded a 6.54% YoY rise in revenue. This growth was driven by an increase in the number of patients and the improvement in the quality of services offered in the hospital sector.
This, in turn, had a positive impact on sales in the pharmacy sector, further boosting the overall revenue.
In H2 2024, the company’s net profit slumped 65% YoY to SAR 8.7 million, from SAR 24.61 million.
On a sequential basis, net earnings dropped 33% from SAR 13.04 million in H1 2024.
Shareholders’ equity reached SAR 199.66 million by Dec. 31, 2024, compared to SAR 180.09 million in the prior-year period.
Kindly,
you can view the full report by subscribing to the Advanced Package
The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: